Glenmark Pharmaceuticals ltd — Capital/Financing Update 2023

Jan 17, 2023

==> picture [33 x 32] intentionally omitted <==

==> picture [148 x 45] intentionally omitted <==

January 17, 2023

To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, The National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001. Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

Sub: Glenmark Pharmaceuticals Ltd. to divest select brands and sub-brands (“Tail Brands” from its dermatology segment, for India and Nepal territories, to Eris Oaknet Healthcare Private Limited

With reference to the subject mentioned above, kindly find attached notification which is self-explanatory.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully, For Glenmark Pharmaceuticals Limited

HARISH Digitally signed by HARISH VINAYAK VINAYAK KUBER KUBER Date: 2023.01.17 17:47:18 +05'30'

Harish Kuber Company Secretary & Compliance Officer

Encl: as above

Glenmark Pharmaceuticals Ltd. Glenmark House, B D Sawant Marg, Andheri (E), Mumbai 400 099 T: 91 22 4018 9999 F: 91 22 4018 9988 CIN: L24299MH1977PLC019982 W: www.glenmarkpharma.com Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com

==> picture [596 x 80] intentionally omitted <==

Exchange Notification

Subject: Glenmark Pharmaceuticals Ltd. to divest select brands and sub-brands (“Tail Brands”) from its dermatology segment, for India and Nepal territories, to Eris Oaknet Healthcare Private Limited.

Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global pharmaceuticals company, today announced that it has entered into an agreement with Eris Oaknet Healthcare Private Limited, a wholly owned subsidiary of ERIS LIFESCIENCES LIMITED to divest the Tail Brands from its dermatology segment, for India and Nepal territories, for a consideration amount of INR 340.48 Cr. The divested Tail Brands include Onabet, Halovate, Sorvate, Luligee, Demelan, Aceret, Dosetil, Revize, and Powercort, and their sub-brands.

According to IQVIA™ sales data (SSA MAT Dec. 2022) for the 12-month period ending December 2022, Glenmark is ranked second in the dermatology therapy area in India. This divestment is in line with Glenmark’s strategy of focusing on its leading brands in the dermatology segment. Going forward, the company will continue to further consolidate its position in its core therapeutic areas of cardiometabolic, respiratory, dermatology, and oncology.

---End---

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation-driven, global pharmaceutical company with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2021. Glenmark has impacted over 2.6 million lives over the last decade through its CSR interventions. For more information, visit www.glenmarkpharma.com. You can follow us on LinkedIn (Glenmark Pharmaceuticals) and Instagram (glenmark_pharma).

==> picture [593 x 29] intentionally omitted <==